About this campaign
Looks like your text is -170 character over the limit. Please shorten it to 200 characters or less.
Looks like your text is -170 character over the limit. Please shorten it to 200 characters or less.
Karsyn has been accepted into the KOALA study!!! (NNZ-2951) This is Phase 3 clinical trial led by Neuren Pharmaceuticals evaluating a potential treatment for Phelan-McDermid syndrome (PMS), a rare genetic condition causing developmental delay, absent speech, and hypotonia. The trial investigates the efficacy and safety of a new drug candidate in addressing key symptoms associated with this, often, SHANK3-related disorder.
Looks like your text is -9574 character over the limit. Please shorten it to 10000 characters or less.
